Havana, Mar 22 (Prensa Latina) Cuban scientists today described as encouraging the results of the studies of the national CIMAvax-EGF vaccine, which is also participating in clinical trials jointly with the United States.
In a meeting with the Cuban president, Miguel Díaz-Canel, the researcher at the Molecular Immunology Center, Tania Crombet, offered details about the research phases of the drug, unique in the world for its effectiveness in treating patients with some types of breast cancer. lung.
According to the expert, in the United States this is one of the leading products of the studies carried out together with the Roswell Park Institute.
“As it was the first time they used the vaccine, the regulatory agency of that nation proposed that it be applied in the worst niche of patients and also the combination was made with one of the molecules that we do not have in Cuba as a result of the blockade,” he stressed. .
The use of this drug has led to a long survival of patients, according to specialists from the Hermanos Ameijeiras Hospital in this capital, one of the institutions where the studies were carried out on the island.
At another point in the meeting, the scientists warned about an increase in cases of Covid-19 in Cuba and urged to maintain the investigation and prevention measures.
The dean of the Faculty of Mathematics of the University of Havana, Raúl Gunivart, confirmed the trend of an increase in patients in the coming days.
The Ministry of Public Health reported today that 679 people with Covid-19 were detected in the last few hours, after analyzing 8,740 samples.
—
